Acquired resistance to a dual erbB1 and erbB2 kinase inhibitors

被引：0
|
作者：
Bacus, Sarah S.
Hill, Jason
Spector, Neil
机构：
[1] Targeted Mol Diagnost LLC, Westmont, IL USA
[2] GlaxoSmithKline, Res Triangle Pk, NC USA
来源：
CANCER RESEARCH | 2006年 / 66卷 / 08期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
2517
引用
收藏
页数：1
相关论文
共 50 条
  • [1] Acquired Resistance to Small Molecule ErbB2 Tyrosine Kinase Inhibitors
    Chen, Franklin L.
    Xia, Wenle
    Spector, Neil L.
    CLINICAL CANCER RESEARCH, 2008, 14 (21) : 6730 - 6734
  • [2] Truncated ErbB2 Expressed in Tumor Cell Nuclei Contributes to Acquired Therapeutic Resistance to ErbB2 Kinase Inhibitors
    Xia, Wenle
    Liu, Zuguo
    Zong, Rongrong
    Liu, Leihua
    Zhao, Sumin
    Bacus, Sarah S.
    Mao, Yubin
    He, Jia
    Wulfkuhle, Julia D.
    Petricoin, Emanuel F., III
    Osada, Takuya
    Yang, Xiao-Yi
    Hartman, Zachary C.
    Clay, Timothy M.
    Blackwell, Kimberly L.
    Lyerly, Herbert K.
    Spector, Neil L.
    MOLECULAR CANCER THERAPEUTICS, 2011, 10 (08) : 1367 - 1374
  • [3] Dual ErbB1/ErbB2 tyrosine kinase inhibition - a potential adjunct to systemic chemotherapy in bladder cancer
    McHugh, LA
    Griffiths, TRL
    Kriajevska, M
    Mellon, JK
    BJU INTERNATIONAL, 2005, 95 : 64 - 65
  • [4] In vivo antitumor efficacy of TAK-285, a novel ErbB1/ErbB2 dual kinase inhibitor
    Iwahara, A.
    Tamura, T.
    Takagi, S.
    Kamiguchi, H.
    Yusa, T.
    Ohta, Y.
    EJC SUPPLEMENTS, 2008, 6 (12): : 99 - 100
  • [5] Dual targeting of ErbB1 and ErbB2 enhances response to chemotherapy in ErbB2 overexpressing breast cancer cell lines.
    O'Donovan, N.
    Clynes, M.
    Crown, J.
    BREAST CANCER RESEARCH AND TREATMENT, 2006, 100 : S105 - S105
  • [6] A Holistic In silico Approach to Develop Novel Inhibitors Targeting ErbB1 and ErbB2 Kinases
    Hu, Jian-Bin
    Dong, Ming-Jun
    Zhang, Jun
    TROPICAL JOURNAL OF PHARMACEUTICAL RESEARCH, 2016, 15 (02) : 231 - 239
  • [7] Ploidy, expression of erbB1, erbB2, P53 and amplification of erbB1, erbB2 and erbB3 in non-small cell lung cancer
    Reinmuth, N
    Brandt, B
    Kunze, WP
    Junker, K
    Thomas, M
    Achatzy, R
    Scheld, HH
    Semik, M
    EUROPEAN RESPIRATORY JOURNAL, 2000, 16 (05) : 991 - 996
  • [8] Dual inhibition of ErbB1 (EGFR/HER1) and ErbB2 (HER2/neu)
    Reid, Alison
    Vidal, Laura
    Shaw, Heather
    de Bono, Johann
    EUROPEAN JOURNAL OF CANCER, 2007, 43 (03) : 481 - 489
  • [9] Receptor tyrosine kinase ERBB4 mediates acquired resistance to ERBB2 inhibitors in breast cancer cells
    Canfield, Kaleigh
    Li, Jiaqi
    Wilkins, Owen M.
    Morrison, Meghan M.
    Ung, Matthew
    Wells, Wendy
    Williams, Charlotte R.
    Liby, Karen T.
    Vullhorst, Detlef
    Buonanno, Andres
    Hu, Huizhong
    Schiff, Rachel
    Cook, Rebecca S.
    Kurokawa, Manabu
    CELL CYCLE, 2015, 14 (04) : 648 - 655
  • [10] Dual ErbB1 and ErbB2 receptor tyrosine kinase inhibition exerts synergistic effect with conventional chemotherapy in pancreatic cancer
    Singla, Smit
    Pippin, James A.
    Drebin, Jeffrey A.
    ONCOLOGY REPORTS, 2012, 28 (06) : 2211 - 2216
12345